Valeant Pharmaceuticals International (VRX) Given Coverage Optimism Score of 0.11
News stories about Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Valeant Pharmaceuticals International earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 44.9208964612195 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- Valeant Pharmaceuticals International, Inc. (VRX) Rating Reiterated by HC Wainwright (americanbankingnews.com)
- Valeant Pharmaceuticals International, Inc. (VRX) Lifted to “Sell” at Vetr Inc. (americanbankingnews.com)
- Valeant Pharma (VRX) Unit, Solta Medical, Granted FDA 510(k) Clearance for Thermage FLX System (streetinsider.com)
- Valeant Pharmaceuticals International, Inc. – Value Analysis (NYSE:VRX) : October 4, 2017 (finance.yahoo.com)
- Valeant Pharmaceuticals International, Inc. (VRX) Earns “Hold” Rating from Canaccord Genuity (americanbankingnews.com)
Valeant Pharmaceuticals International (VRX) opened at 14.46 on Monday. The company’s market capitalization is $5.04 billion. The stock has a 50 day moving average price of $14.01 and a 200-day moving average price of $13.42. Valeant Pharmaceuticals International has a 1-year low of $8.31 and a 1-year high of $24.30.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. The company had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. Valeant Pharmaceuticals International’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.88) EPS. Equities analysts predict that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.
VRX has been the subject of several recent research reports. Royal Bank Of Canada set a $19.00 price objective on Valeant Pharmaceuticals International and gave the stock a “sector perform” rating in a report on Monday, June 19th. Zacks Investment Research lowered Valeant Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Thursday, July 13th. ValuEngine lowered Valeant Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Wells Fargo & Company dropped coverage on Valeant Pharmaceuticals International in a report on Sunday, July 30th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $23.00 price objective on shares of Valeant Pharmaceuticals International in a report on Tuesday, August 29th. Five equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $17.73.
WARNING: “Valeant Pharmaceuticals International (VRX) Given Coverage Optimism Score of 0.11” was published by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.watchlistnews.com/valeant-pharmaceuticals-international-vrx-given-coverage-optimism-score-of-0-11/1618655.html.
In other news, Director Schutter Richard U. De bought 10,000 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were bought at an average cost of $14.33 per share, with a total value of $143,300.00. Following the acquisition, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.87% of the stock is currently owned by corporate insiders.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.